Inactivation of TNF signaling by rationally designed dominant-negative TNF variants
about
TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative diseaseHigh-resolution structural and thermodynamic analysis of extreme stabilization of human procarboxypeptidase by computational protein designTumour necrosis factor-mediated macrophage activation in the target organ is critical for clinical manifestation of uveitisDesign of protein-ligand binding based on the molecular-mechanics energy modelTNF biology, pathogenic mechanisms and emerging therapeutic strategiesSoluble TNF mediates the transition from pulmonary inflammation to fibrosisAAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's diseaseMultimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.Crystal structure of TNFα complexed with a poxvirus MHC-related TNF binding proteinInhibition of soluble tumor necrosis factor ameliorates synaptic alterations and Ca2+ dysregulation in aged ratsDifferential expression and tumor necrosis factor-mediated regulation of TNFRSF11b/osteoprotegerin production by human melanomas.Structure-based redesign of the binding specificity of anti-apoptotic Bcl-x(L).Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia.Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microgliaHippocampal TNFα Signaling Contributes to Seizure Generation in an Infection-Induced Mouse Model of Limbic Epilepsy.Adipocyte inflammation is essential for healthy adipose tissue expansion and remodelingReactivation of M. tuberculosis infection in trans-membrane tumour necrosis factor mice.Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology.Central but not systemic administration of XPro1595 is therapeutic following moderate spinal cord injury in miceRecent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities.Manipulation of receptor oligomerization as a strategy to inhibit signaling by TNF superfamily membersDelayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's diseaseDifferential requirements for soluble and transmembrane tumor necrosis factor in the immunological control of primary and secondary Listeria monocytogenes infectionDesigned tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis.Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelinationComputational design of variant TNF molecules: a novel methodology for inhibition of proinflammatory cascades.A novel anti-TNF scFv constructed with human antibody frameworks and antagonistic peptides.Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders.Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15.Design of effective immunotherapy for human autoimmunity.Estrogens and aspects of prostate disease.The relevance of kinin B1 receptor upregulation in a mouse model of colitisTransmembrane TNF-TNFR2 Impairs Th17 Differentiation by Promoting Il2 Expression.Immunochemical termination of self-toleranceThe TNFα-Transgenic Rat: Hippocampal Synaptic Integrity, Cognition, Function, and Post-Ischemic Cell Loss.Inhibition of Soluble Tumor Necrosis Factor Prevents Chemically Induced Carcinogenesis in MicePeripheral elevation of TNF-α leads to early synaptic abnormalities in the mouse somatosensory cortex in experimental autoimmune encephalomyelitisBlocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's diseaseIntranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats
P2860
Q21093232-4810F560-5C77-4069-A71F-A5F9C0240A4BQ24628092-274E3713-02DA-49BF-8081-F63FE7E0B014Q24633598-9C6AE37D-E8CD-4D60-BBA3-14B811F1544BQ24651388-750F3DF3-8FEE-468A-8140-982D126A080AQ26776492-74D439B8-4792-4993-ACC2-0E6E10D87A2DQ27303153-BDB4109F-FF63-47FF-8A6B-DC538494E358Q27334472-3BACB273-3901-42D4-96A6-EFE297B39DF2Q27472925-C8222730-2DC6-4FC5-B748-E32235D24482Q27657836-B360523B-1B2B-4719-8D07-9114A023681DQ28577238-6F56044E-9B2E-4C97-8AEF-3095C5C3D82FQ30412235-8A42EE34-3F4E-4B38-95D7-D1C8C8BD76D7Q30423652-04A06003-F350-4A4F-B4C0-A9346CD183ADQ30610169-2C1C49BC-49F3-41C1-AF4A-F7D8DC6461E6Q33578973-2312E464-C4E0-48B2-8FEC-C79FD6BDBA41Q33651396-4376CFAA-1B59-440F-8521-CAF258FC2BD5Q33838623-9F30C94F-2A5F-4053-A03E-7EF7B318FB51Q34087566-5F6B9C31-9611-46A8-9ABF-0F133A61BB84Q34169743-44C0A17E-D5DD-45C8-A061-79D2F1357D20Q34250544-C5663A8E-8CCF-4CD9-88DC-8C583A1E6E74Q34327203-2748B522-AEEB-49F2-B06A-CB277A214C33Q34386821-38A3768D-379D-4D3C-AF76-348537D834FDQ34473323-A35D4226-9E85-4363-B9FD-6D6F2EF38CCAQ34681089-581E5E03-32D6-4C17-A6DE-1706F05EBC0CQ34695283-270B4D0C-9B43-4337-BED5-18F1F67DE16DQ35108700-F157A598-06E0-4412-9D1D-5F14BFCF1928Q35206971-0AA93A4D-F182-472F-AAD4-2E02C57227ECQ35581656-ACA949C8-A8E2-42C3-AF8C-201389848189Q35658998-3ABFEEDB-015D-42E9-986B-AA9CAFF73AC9Q35782879-1CA68117-3984-4358-A186-B7E9926665DEQ35883106-893BA1A7-C340-4F98-95E7-15E16488ECCBQ36148416-81271635-F2F0-4C9D-8392-CC175B9E061EQ36697811-38B7EDB0-01F8-4044-A546-1248D0515158Q36790176-4815D682-1943-4824-B235-107924D65567Q36826546-B02FA708-B244-4D83-B061-0B1ED43B5C90Q36837408-214FB10D-156F-431E-9659-999DED029CA6Q36868735-2D172085-E67D-4F3B-BBA0-FF1444F1DC25Q36917707-E5717CC8-202A-411B-A175-953F3A88E2B2Q36950333-D45BE5C7-2BA0-4F4C-87E1-A9F1C1EE626BQ36998952-DAFED41D-7FB2-4EDA-8E65-4C1586BD1DF7Q37162724-96E32F48-807B-42C4-B19E-24AB5DF31832
P2860
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants
@ast
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants
@en
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants
@en-gb
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants
@nl
type
label
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants
@ast
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants
@en
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants
@en-gb
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants
@nl
prefLabel
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants
@ast
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants
@en
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants
@en-gb
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants
@nl
P2093
P921
P3181
P356
P1433
P1476
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants
@en
P2093
Anton V Filikov
Araz Eivazi
Arthur J Chirino
Bassil I Dahiyat
Cheryl Chan
Christina Abbott
Christopher O'Brien
David Carmichael
Donald O'Keefe
P304
P3181
P356
10.1126/SCIENCE.1081297
P407
P577
2003-09-26T00:00:00Z